Understand what your hormone testing results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Testosterone and ApoB together: Hormone status meets atherogenic particle load
Testosterone / ApoB blood testing measures two distinct molecules with big biological roles: testosterone, a steroid hormone, and apolipoprotein B (ApoB), a structural protein on cholesterol-carrying particles. Testosterone is made mainly in the testes, with smaller amounts from the ovaries and adrenal glands. ApoB is produced in the liver (ApoB‑100) and intestine (ApoB‑48) and is built into the surface of lipoproteins that move fats through the bloodstream—especially VLDL and LDL, often called “bad cholesterol.”
Testosterone drives reproductive function, sexual development, muscle and bone maintenance, red blood cell production, energy, and libido (androgen/sex‑steroid signaling). ApoB acts as the required “address tag” that lets fat-rich particles be assembled, released, and taken up by tissues; because each LDL-type particle carries one ApoB molecule, the ApoB level reflects the number of artery-entering particles in circulation (atherogenic lipoprotein particle burden). Together, these measurements capture two fundamentals: hormonal status that shapes body composition and vitality, and lipid transport that influences how fats are delivered to—and can accumulate within—artery walls.
Why looking at testosterone alongside ApoB clarifies cardiometabolic risk in men
This combined test looks at two core axes of health: testosterone, the body’s primary anabolic sex hormone, and apolipoprotein B (ApoB), the protein “tag” on LDL and related particles that deliver cholesterol and can seed plaque. Together they link energy, strength, and reproductive signaling with the number of artery‑entering particles that drive atherosclerosis.
Big picture: testosterone shapes body composition, mood, and metabolic rate, which in turn influence lipids; ApoB quantifies the particles that actually deliver cholesterol into artery walls. Together they frame vitality and long‑term cardiovascular risk.
Low, mid, and high pairings — what the testosterone/ApoB picture suggests
In adults, total testosterone is much higher in men than women, peaks in late teens/20s, and falls with age; people tend to feel best when values sit in the mid range for their age and sex. ApoB varies less by sex and is considered more favorable toward the low end of its reference interval because fewer atherogenic particles means lower plaque exposure.
When testosterone runs low, physiology shifts toward reduced protein synthesis and lower dopamine/androgen signaling: fatigue, low libido, depressed mood, reduced muscle and bone, and sometimes anemia. In women, very low values can blunt sexual desire and vitality; in teens it may impair pubertal progression. Very low ApoB usually reflects few LDL particles and lower vascular risk; if extreme, it can signal malabsorption or rare genetic hypobetalipoproteinemia.
When testosterone runs high, men may see acne, oily skin, irritability, and elevated red blood cells; women can develop hirsutism, acne, and irregular periods (often with ovarian androgen excess). High ApoB indicates many LDL/VLDL particles, a strong driver of plaque formation, especially with insulin resistance or diabetes.
Caveats that nudge testosterone or ApoB outside of underlying biology
Notes: Testosterone peaks in the morning; total versus free depends on sex hormone–binding globulin (SHBG), influenced by age, thyroid status, estrogens, and liver disease. LC–MS assays are more accurate at low testosterone than immunoassays. ApoB is relatively fasting-independent; lipoprotein(a) is included within ApoB. Pregnancy and acute illness alter both.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Where the testosterone/ApoB pair fits in a longevity-focused panel
This paired test assesses testosterone, the chief androgen, and ApoB, the number of atherogenic lipoprotein particles. Together they link anabolic signaling and lipid transport to energy, body composition, fertility, cognition, and cardiovascular risk.
Low values usually reflect reduced androgen effect or fewer atherogenic particles. Low testosterone in men indicates underproduction or high binding (low free fraction), with lower energy, libido, muscle, and bone; in women, dampened desire and bone accrual. Low ApoB means fewer plaque-forming particles; very low may reflect impaired lipoprotein production or malabsorption/liver disease. With age testosterone declines; pregnancy lowers free testosterone and tends to raise ApoB.
Being in range suggests age-appropriate androgen signaling and an ApoB particle burden compatible with healthy lipid transport. For ApoB, lower within normal is generally favored for vascular protection. For testosterone, mid-range for age/sex often aligns with stable physiology.
High values usually reflect increased production/exposure or impaired clearance. High testosterone from exogenous androgens or low binding proteins can drive acne and elevated red cells in males, and hirsutism, acne, and irregular cycles in females (hyperandrogenism/PCOS). High ApoB denotes many atherogenic particles from overproduction or slow clearance and higher plaque risk.
Frequently Asked Questions
References
- Chen Z, Zhang E, Gan L, Jiang G, Duan Q, Huang M, Li H, Huang G (2024). Analysis of the association between testosterone and cardiovascular disease potential risk factor apolipoprotein B in adult males without cancer: National Health and Nutrition Examination Survey 2011-2016. *Frontiers in Endocrinology*, *15*, 1304344. https://doi.org/10.3389/fendo.2024.1304344
- Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. *Circulation: Cardiovascular Quality and Outcomes*, *4*(3), 337-345. https://doi.org/10.1161/CIRCOUTCOMES.110.959247
- Feingold KR (2024). *Introduction to lipids and lipoproteins*. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
- Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, ... Catapano AL (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, *38*(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, ... Wiklund O (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias. *European Heart Journal*, *41*(1), 111-188. https://doi.org/10.1093/eurheartj/ehz455
